Sinclair Pharma PLC (SPH) Given Consensus Rating of “Buy” by Brokerages
Sinclair Pharma PLC (LON:SPH) has earned an average rating of “Buy” from the seven research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is GBX 54 ($0.70).
A number of analysts recently commented on the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 71 ($0.92) target price on shares of Sinclair Pharma PLC in a research report on Tuesday, July 11th. Peel Hunt reaffirmed a “buy” rating and issued a GBX 68 ($0.88) target price on shares of Sinclair Pharma PLC in a research report on Monday, June 19th.
Shares of Sinclair Pharma PLC (LON SPH) opened at 29.00 on Tuesday. The firm’s 50-day moving average price is GBX 29.38 and its 200-day moving average price is GBX 31.48. Sinclair Pharma PLC has a 12 month low of GBX 26.00 and a 12 month high of GBX 36.35. The firm’s market capitalization is GBX 145.64 million.
Sinclair Pharma PLC Company Profile
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.